Literature DB >> 18488144

The clinical diagnosis of heparin-induced thrombocytopenia in patients receiving continuous renal replacement therapy.

Chris E Holmes1, Joe C Huang, Carina Cartelli, Alan Howard, Jeffrey Rimmer, Mary Cushman.   

Abstract

BACKGROUND: Thrombocytopenia is common in critically ill patients who receive continuous renal replacement therapy. Often, these patients receive heparin therapy and the diagnosis of heparin induced thrombocytopenia (HIT) is considered as a potential etiology. No data regarding the clinical diagnosis of HIT is available for patients receiving continuous renal replacement therapy. PATIENTS AND METHODS: We performed a retrospective study of 29 consecutive patients who received CRRT in a medical-surgical intensive care unit (ICU) and determined trends in platelet counts following CRRT and the frequency of meeting platelet based clinical criteria for consideration of a HIT diagnosis.
RESULTS: For patient exposures to CRRT concurrent with heparin, 54% met at least one clinical threshold for consideration of the diagnosis of HIT. In 31% of exposures, both a platelet count <100,000/mm3 and a >50% decrease from baseline were seen. In contrast, the majority (73-85%) of patients receiving CRRT had a low pre-test probability of HIT using the "4T's" scoring system. Mean platelet counts while on CRRT concurrent with heparin were significantly lower than when patients received heparin alone (P < 0.02).
CONCLUSIONS: The clinical diagnosis of HIT in ICU patients initiating CRRT is challenging given the decrease in platelet counts seen following CRRT initiation in the majority of patients. A prospective study in this population is needed to optimize patient outcomes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18488144     DOI: 10.1007/s11239-008-0228-8

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  29 in total

1.  Evaluation of a pharmacy-based surveillance program for heparin-induced thrombocytopenia.

Authors:  A C Andreescu; C Possidente; M Hsieh; M Cushman
Journal:  Pharmacotherapy       Date:  2000-08       Impact factor: 4.705

2.  Temporal aspects of heparin-induced thrombocytopenia.

Authors:  T E Warkentin; J G Kelton
Journal:  N Engl J Med       Date:  2001-04-26       Impact factor: 91.245

Review 3.  Heparin-induced thrombocytopenia: towards consensus.

Authors:  T E Warkentin; B H Chong; A Greinacher
Journal:  Thromb Haemost       Date:  1998-01       Impact factor: 5.249

4.  Frequency of antibodies directed against heparin-platelet factor 4 in patients exposed to heparin through chronic hemodialysis.

Authors:  M de Sancho; M G Lema; J Amiral; J Rand
Journal:  Thromb Haemost       Date:  1996-04       Impact factor: 5.249

5.  Thrombocytopenia in a surgical ICU.

Authors:  F Stéphan; J Hollande; O Richard; A Cheffi; M Maier-Redelsperger; A Flahault
Journal:  Chest       Date:  1999-05       Impact factor: 9.410

6.  Thrombocytopenia in medical-surgical critically ill patients: prevalence, incidence, and risk factors.

Authors:  Mark A Crowther; Deborah J Cook; Maureen O Meade; Lauren E Griffith; Gordon H Guyatt; Donald M Arnold; Christian G Rabbat; William H Geerts; Theodore E Warkentin
Journal:  J Crit Care       Date:  2005-12       Impact factor: 3.425

7.  Epidemiology, management, and outcome of severe acute renal failure of critical illness in Australia.

Authors:  W Silvester; R Bellomo; L Cole
Journal:  Crit Care Med       Date:  2001-10       Impact factor: 7.598

8.  Role of contact system activation in hemodialyzer-induced thrombogenicity.

Authors:  R D Frank; J Weber; H Dresbach; H Thelen; C Weiss; J Floege
Journal:  Kidney Int       Date:  2001-11       Impact factor: 10.612

9.  Thrombosis and hemorrhage in heparin-induced thrombocytopenia in seriously ill patients.

Authors:  Jos P J Wester; Fred J L M Haas; Douwe H Biesma; J A Leusink; Gerda Veth
Journal:  Intensive Care Med       Date:  2004-05-20       Impact factor: 17.440

10.  Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low-molecular-weight heparin.

Authors:  J Amiral; E Peynaud-Debayle; M Wolf; F Bridey; A M Vissac; D Meyer
Journal:  Am J Hematol       Date:  1996-06       Impact factor: 10.047

View more
  2 in total

1.  Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19.

Authors:  Jing-Chun Song; Gang Wang; Wei Zhang; Yang Zhang; Wei-Qin Li; Zhou Zhou
Journal:  Mil Med Res       Date:  2020-04-20

2.  Expert consensus on the diagnosis and treatment of thrombocytopenia in adult critical care patients in China.

Authors:  Jing-Chun Song; Shu-Yuan Liu; Feng Zhu; Ai-Qing Wen; Lin-Hao Ma; Wei-Qin Li; Jun Wu
Journal:  Mil Med Res       Date:  2020-04-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.